Guizhou Bailing Group Pharmaceutical Co., Ltd.

SZSE:002424.SZ

7.99 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

20232022202120202019201820172016201520142013201220112010200920082007
Revenue 4,262.9713,540.1323,111.653,087.8882,850.5853,136.8432,591.8172,214.2111,899.0881,574.6721,405.331,367.5821,138.427863.756734.518607.359446.204
Cost of Revenue 1,952.771,411.9231,256.3771,345.1241,136.7481,262.654951.969788.955720.559616.203559.133622.213508.335412.085397.864323.769229.181
Gross Profit 2,310.2022,128.2091,855.2721,742.7641,713.8381,874.191,639.8471,425.2561,178.529958.47846.197745.369630.092451.672336.654283.59217.023
Gross Profit Ratio 0.5420.6010.5960.5640.6010.5970.6330.6440.6210.6090.6020.5450.5530.5230.4580.4670.486
Reseach & Development Expenses 42.0422.40430.42536.99724.79130.84737.48224.47121.31716.4098.6186.3333.2192.448000
General & Administrative Expenses 82.29878.79759.93978.31360.1946.29243.08439.46338.11843.73425.49430.31923.25222.47440.69539.18724.828
Selling & Marketing Expenses 1,907.1531,530.3761,288.6781,135.454970.365933.127782.342613.795456.904392.509362.532354.463262.228192.05144.207123.42691.262
SG&A 2,630.2161,609.1731,348.6171,213.7671,030.554979.418825.426653.258495.023436.243388.027384.781285.48214.525184.902162.613116.09
Other Expenses 120.824173.121164.121156.224148.6051.572-6.21710.39521.5845.7926.64736.7653.74922.3310.653-1.7481.09
Operating Expenses 2,794.6181,804.6981,543.1631,406.9881,203.951,155.471979.499818.308648.46547.962481.802460.003345.782249.237192.138168.483120.499
Operating Income -484.417357.964277.905418.793493.254664.252626.416569.902470.634371.529319.9253.737238.325183.232130.80999.4186.396
Operating Income Ratio -0.1140.1010.0890.1360.1730.2120.2420.2570.2480.2360.2280.1860.2090.2120.1780.1640.194
Total Other Income Expenses Net -8.653-198.908-26.983-210.023-137.5071.5725.78810.35221.2655.5776.26-17.282-37.922-9.539-12.182-17.429-7.975
Income Before Tax -493.069159.056147.758208.77355.747665.824632.204579.944491.899377.106326.159263.384241.972189.557131.45196.83687.486
Income Before Tax Ratio -0.1160.0450.0470.0680.1250.2120.2440.2620.2590.2390.2320.1930.2130.2190.1790.1590.196
Income Tax Expense -80.60523.08631.0755.04471.19694.057100.17493.68275.75162.05253.16534.52431.99231.35819.78416.5415.489
Net Income -414.511138.474118.483152.375282.749563.239526.137482.327411.375310.478269.604221.752208.381158.198111.66780.29671.905
Net Income Ratio -0.0970.0390.0380.0490.0990.180.2030.2180.2170.1970.1920.1620.1830.1830.1520.1320.161
EPS -0.30.0990.0850.110.20.40.370.340.290.220.190.160.150.130.170.0760.068
EPS Diluted -0.30.0990.0850.110.20.390.370.340.290.220.190.160.150.120.170.0760.068
EBITDA -298.608370.048353.408412.7548.395757.862706.835663.623563.645462.048404.927324.403288.358210.458158.285125.221108.923
EBITDA Ratio -0.070.1340.1240.1670.2040.2710.2850.3160.3380.3180.3090.2880.3020.270.2170.2080.246